Abstract
During cancer progression malignant cells undergo epithelial-mesenchymal transitions (EMTs) and mesenchymal-epithelial transitions (METs) as part of a broad invasion and metastasis program. We previously observed MET events among lung metastases in a preclinical model of prostate adenocarcinoma that suggested a relationship between epithelial plasticity and metastatic spread. We thus sought to translate these findings into clinical evidence by examining the existence of EMT in circulating tumor cells (CTCs) from patients with progressive metastatic solid tumors, with a focus on men with castration-resistant prostate cancer (CRPC) and women with metastatic breast cancer (BC). We show that the majority (>80%) of these CTCs in patients with metastatic CRPC co-express epithelial proteins such as EpCAM, CK, and E-cadherin, mesenchymal proteins, including vimentin, N-cadherin, and O-cadherin, and the stem cell marker CD133. Equally, we find that over 75% of CTCs from women with metastatic BC co-express cytokeratin, vimentin, and N-cadherin. The existence and high frequency of these CTCs co-expressing epithelial, mesenchymal, and stem-cell markers in patients with progressive metastases has important implications for the application and interpretation of approved methods to detect CTCs.
Introduction
Most metazoan cells can be classified as either epithelial or mesenchymal based on morphology, behavior and molecular signatures. In adult animals epithelial and mesenchymal cells usually remain in one phenotypic state; that is, epithelial cells do not change their properties and become mesenchymal. During development, however, epithelial cells of the early embryo give rise to all three embryonal layers (endoderm, mesoderm and ectoderm), which include mesenchymal cells (1) . Therefore, these early embryonal cells have the ability to transition between epithelial and mesenchymal states, a property we define as epithelial plasticity (for a slightly different definition see (2) ).
Indeed, observations in embryos demonstrated epithelial-mesenchymal transitions (EMTs) as well as mesenchymal-epithelial transitions (METs) (3), which may be viewed, perhaps naively, as forward and reverse directions of the same reaction mechanism (for review, see (2, 4) ).
While it is convenient to present EMT/MET as a reversible reaction between binary states, there are suggestions that intermediate states exist and that these may play important roles. The importance of EMT and MET in cancer progression is now widely, albeit not unanimously, accepted (see recent reviews (4) (5) (6) (7) (8) ). EMT is observed in human cancer cells in vitro and in xenografts, and in the leading edge of invasive carcinomas in vivo (5, 6) . In human prostate carcinoma, loss of E-cadherin expression and over-expression of N-cadherin, which indicates the presence of an EMT, independently correlates with high
Gleason score and systemic and metastatic recurrence after surgery, linking EMT to more aggressive clinical behavior (9) (10) (11) (12) . In addition, recent studies have demonstrated the importance of N-cadherin expression during castrationresistant metastatic progression in preclinical models of prostate cancer and in human metastases These translational studies have suggested a link between loss of epithelial markers, gain of mesenchymal markers, and the induction of signaling pathways that promote survival and androgen-receptor independent growth (13) . In breast cancer, a similar link has been established between EMT markers in primary and disseminated bone marrow tumor cells and aggressive clinical behavior (14) (15) (16) (17) (18) . Likewise, evidence for MET was obtained from microscopic analysis of colorectal carcinoma metastases, which adopted epithelial characteristics of the non-invasive regions of the primary tumor (19) . In prostate cancer, attachment of metastatic cells to bone cells correlates with expression of E-cadherin (20) . These and many other studies describe the existence of these transitions during carcinogenesis and raise questions about their functional importance. There is strong evidence that EMT is important for metastatic behavior and chemoresistance (18, 21) ; however, the importance of MET has been more difficult to ascertain. Previously, we found that the preponderance of MET events among lung metastases in rats bearing AT3 rat prostate adenocarcinoma tumors suggested an important functional relationship between the capacity to revert to a more epithelial state and metastatic growth in the lung parenchyma (22, 23) .
A strict view of epithelial plasticity in cancer posits that a mesenchymallike state reached post-EMT is the driver of malignant fitness. Indeed there is strong evidence that the mesenchymal properties of invasiveness and motility are required for metastases (see above) and that EMT leads to expression of cancer stem cell markers, including CD44 (24) . Nonetheless, observations above suggest that mesenchymal properties per se are not sufficient for optimal malignant behavior (19, 22, 23, 25) . A broader interpretation suggests that the ability to easily transition between epithelial-like and mesenchymal-like states, which we define as phenotypic plasticity, may be linked to stem cell-like properties and is a more important determinant of aggressive metastatic behavior than the properties of the end states. In a preclinical model examining the importance of stem cells and cancer growth, subcutaneous injection of CD133-positive cells, which are predicted to be stem-cell like, into immunodeficient mice causes tumor growth, whereas injection of CD133-negative cells do not (26) . A recent clinical study that measured mRNAs coding for stem-like markers in the bloodstream of patients with resected colorectal cancer found that the expression of CD133, CEA, and cytokeratin RNAs was associated with recurrent disease and an overall poor prognosis (27) .
Therefore, we posit that the most plastic cells will be those that inhabit transitional or intermediate states with properties of both epithelium and mesenchyme, and that these transitional cells will be particularly malignant and stem-like. In order to test this proposal in human disease, we sought evidence for markers of both mesenchymal and stemness phenotypes in CTCs from patients with metastatic castration-resistant prostate cancer (CRPC) and metastatic breast cancer (BC). 
Materials and Methods

Analysis of human circulating tumor cells
Patients eligible for the CTC biomarker protocols included 1) men with mCRPC, with metastatic progression by PSA (two consecutive rises over nadir separated by >1 week) or radiologic criteria (RECIST or new bone scan lesions), a PSA >5, age >18 years; or 2) women with mBC with disease progression or with initiation of a new systemic therapy, who were >18 years of age, and who were at least 7 days from treatment with an anthracycline-containing regimen.
All subjects provided informed consent as part of an IRB-approved prospective clinical protocol. Blood (15ml) was collected from patients and processed within 48 hours at the Duke University Department of Molecular Pathology and clinical pathology laboratory using the Cell Search System (Veridex, Raritan, NJ).
Veridex profile kits, which isolate EpCAM positive cells using a ferromagnetic immunoabsorbtion assay without additional staining, were used to collect CTCs.
An additional tube was collected and processed in parallel for CTC enumeration using the Veridex Cellsearch method using the standard test kit. Following profile kit processing, the isolated cells were either processed immediately or stored overnight in 4% paraformaldehyde (PFA) and processed the next day. An initial wash using a bench top magnet to enrich the EpCAM-bound cells was performed to further isolate CTCs, with resuspension of the cell pellet after magnet release into 100 μL PBS. Immunostaining was done on teflon coated slides. Briefly, cells were pipetted into the wells of the slides and left to settle for ~ 30 minutes 
Statistical analyses
We used simple descriptive statistics to estimate the prevalence of mesenchymal and CD133 antigen co-expression on EpCAM-captured CTCs, summarizing these findings on both an intra-individual level and within group 
Results
In order to examine the co-expression of mesenchymal and/or stemness antigens on CTCs from patients with metastatic disease, we took advantage of the existing FDA-approved capture method to initially capture and isolate cells from whole blood. CTCs have both independent prognostic and predictive significance in multiple epithelial malignancies, including mCRPC and mBC (28, 29) , and can be collected, isolated, and analyzed for a variety of biomarkers To test for the existence of mesenchymal-like CTCs, blood was collected from 41 men with mCRPC and 16 women with mBC (see baseline characteristics for the patients in Table 1 and Supplementary Table 2 
205/244 (84%) of CTCs were identified as co-expressing these markers ( Figure   1D & E, Table 2 and also see Supplementary Table 3 The expression of N-cadherin among CTCs varied from undetectable, determined by the real-time negative controls described in
Supplementary Table 1 , to very strong ( Figure 1D ). This variation was observed among CTCs from individual patients as can be seen by examination of three CTCs from patient 11 ( Figure 1E ). While we noted heterogenous vimentin expression among patient and control leukocytes, we did not observe N-cadherin expression among patient or control leukocytes.
Among ten women with mBC, nine had detectable CTCs and of these, we found evidence of vimentin co-expression in seven (78%) patients, and 55/88
CTCs overall (63%) co-expressed vimentin (Supplementary Figure 2 , Table 2 and Supplementary Table 4 , and controls in Supplementary Figure 1) .
Among another six women with detectable CTCs and mBC, four had evidence of CK and N-cadherin co-expression, and overall 78/95 CTCs (82%) had Ncadherin expression, with significant heterogeneity in expression in a given individual ( Table 2 Table 2 and Supplementary   Table 3 with controls in Supplementary Figure 1) . These findings suggest that prostate cancer CTCs co-express adhesion molecules that may promote homing to bone and homotypic binding to osteoblastic cells. 
experimental manipulation of preclinical systems in which either EMT/MET is prevented; future experiments will need to address this issue. Finally, these studies have not correlated co-expression of EMT factors on CTCs with clinical outcomes; these prognostic studies require large appropriately powered studies and patients with long-term follow-up, such as has been recently reported with CD133 positive colorectal CTCs and post-operative outcomes (27) . Our findings, however, suggest that the measurement of CTCs collected through both EpCAMenriched and EMT antigen-enriched methods may complement each other in providing prognostic or predictive information during systemic therapy that should be prospectively evaluated.
Finally, CTCs expressing mesenchymal or stem-like markers expression, which comprise the majority of cells isolated in this study, and additional cells that may go undetected due to EpCAM loss, represent a therapeutic problem. It has been well documented that EMT alters drug sensitivity (21, 41, 42) and it has been challenging to direct therapy to cancer cells with stem cell-like properties, perhaps because of their recalcitrance to undergo apoptosis (43) . While recent studies suggest both a screening method and actual compounds (e.g., salinomycin) that can selectively target cancer stem cells (21) , these aggressive cells still represent a formidable challenge. Our findings suggest that these cell types may be highly prevalent among patients with metastatic epithelial tumors, and suggest methods for the improved detection of these cells in vivo to assist in developing novel therapeutic strategies. 
SITES OF METASTATIC DISEASE
Visceral (lung + liver) 54%
Lymph Node Only 0%
Metastatic to Bone:
Metastatic to Bone With Lymph Nodes (no visceral metastases) 24%
Metastatic to Bone Without Lymph Nodes (no visceral metastases) 22% Table 1 . Baseline demographic and clinical characteristics of the men with metastatic CPRC in this study (n=41).
1 PSA: prostate specific antigen. 2 Pain is scored as a linear analog scale (0-10 range). 
